14-day Premium Trial Subscription Try For FreeTry Free

Range Low Price High Price Comment
30 days $141.16 $183.01 Friday, 3rd May 2024 CYTK stock ended at $65.27. This is 1.45% more than the trading day before Thursday, 2nd May 2024. During the day the stock fluctuated 2.47% from a day low at $65.00 to a day high of $66.61.
90 days $141.16 $227.30
52 weeks $84.73 $227.30

Historical Cytokinetics prices

Date Open High Low Close Volume
Mar 30, 2023 $35.47 $35.70 $34.16 $34.21 838 239
Mar 29, 2023 $35.31 $35.31 $34.60 $35.25 591 218
Mar 28, 2023 $34.36 $35.60 $33.98 $34.98 803 723
Mar 27, 2023 $33.73 $34.64 $33.42 $34.53 539 826
Mar 24, 2023 $33.37 $33.64 $32.96 $33.36 720 685
Mar 23, 2023 $34.80 $34.99 $33.37 $33.63 815 082
Mar 22, 2023 $36.02 $37.45 $34.31 $34.37 804 305
Mar 21, 2023 $35.50 $36.59 $35.06 $36.18 1 414 457
Mar 20, 2023 $35.20 $35.51 $34.55 $35.20 841 089
Mar 17, 2023 $36.87 $36.94 $35.02 $35.33 2 441 321
Mar 16, 2023 $36.99 $37.94 $36.40 $37.06 1 146 129
Mar 15, 2023 $37.34 $37.71 $36.48 $37.27 767 498
Mar 14, 2023 $37.75 $38.39 $37.31 $37.76 895 212
Mar 13, 2023 $35.41 $37.62 $35.07 $37.27 1 499 621
Mar 10, 2023 $36.64 $36.67 $34.40 $35.60 1 812 035
Mar 09, 2023 $39.12 $39.45 $36.51 $36.86 1 190 466
Mar 08, 2023 $39.94 $40.18 $38.53 $39.24 860 214
Mar 07, 2023 $39.29 $40.50 $38.96 $40.11 1 156 485
Mar 06, 2023 $41.74 $41.74 $38.76 $39.13 1 990 533
Mar 03, 2023 $39.73 $42.76 $39.70 $41.95 1 065 949
Mar 02, 2023 $41.57 $42.32 $39.50 $39.60 1 692 690
Mar 01, 2023 $43.22 $43.89 $42.86 $43.11 880 439
Feb 28, 2023 $42.81 $43.60 $42.55 $43.36 1 127 046
Feb 27, 2023 $43.14 $43.27 $42.39 $42.98 445 596
Feb 24, 2023 $42.73 $43.50 $42.30 $42.81 801 809
Click to get the best stock tips daily for free!

About Cytokinetics

Cytokinetics Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in pati... CYTK Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT